Bladder Cancer Recurrence: Carbon Ion Therapy Precisely Targets Tumors While Preserving Quality of L
Bladder Cancer Recurrence: Carbon Ion Therapy Precisely Targets Tumors While Preserving Quality of Life
Bladder cancer is the most common malignant tumor of the urinary system, ranking first in incidence among urological malignancies. It is often referred to as a "lucky cancer" because symptoms typically appear early, allowing most patients to be diagnosed and treated at an early stage with generally favorable outcomes. However, not all patients are so fortunate. For some with recurrent or refractory bladder cancer, radical cystectomy—often the last resort—means a lifetime of relying on a urostomy bag and a significant decline in quality of life. Fifty-five-year-old Mr. Xu faced the same dilemma but, under the meticulous planning of our medical team, underwent carbon ion therapy, successfully preserving his bladder. One month after treatment, the bladder tumor had significantly shrunk, with only mild side effects observed.
Medical History Review: Multiple Recurrences, Traditional Treatments at an Impasse
In October 2024, Mr. Xu was diagnosed with high-grade urothelial carcinoma of the bladder. Despite undergoing two surgeries and chemotherapy, the tumor recurred in February 2025, invading the right seminal vesicle and ureter. Continuing with traditional treatment would likely require a radical cystectomy with urinary diversion, but Mr. Xu, hoping to preserve bladder function, refused the aggressive surgery.
Key Challenges
- Complex tumor location (involving the seminal vesicle, ureteral orifice, and posterior bladder wall), making complete surgical resection difficult.
- Severe side effects from prior chemotherapy (myelosuppression, ureteral dilation, and impaired renal function), resulting in poor tolerance.
Breakthrough Solution: Carbon Ion Therapy – Precise, Effective, and Organ-Preserving
To maximize bladder function preservation, our medical team meticulously designed a carbon ion radiotherapy plan combined with dose-reduced chemotherapy (GC) for Mr. Xu.
Carbon Ion Therapy Plan
Three Core Advantages of Carbon Ion Therapy
✅ Precision Tumor Targeting with Normal Tissue Preservation
● Utilizes the Bragg peak effect to deliver high radiation doses precisely to the tumor while minimizing exposure to surrounding organs (e.g., intestines).
● Significantly lower toxicity compared to conventional radiotherapy: Only Grade 2 urinary frequency and dysuria (mild) occurred during treatment, with minimal radiation-induced proctitis.
✅ Remarkable Efficacy – Tumor Shrinkage Observed Within 1 Month
● Partial response (PR) confirmed at 1-month follow-up, with dramatic reduction in tumor metabolic activity and relief of right ureteral compression.
● Imaging comparison (before vs. after treatment)
✅ Successful Bladder Preservation Without Compromising Quality of Life
● Avoids urinary diversion procedures (e.g., ileal conduit), allowing normal urination and unaffected social and daily activities.
Mr. Xu expressed: "Now I feel completely like a normal person again!"
Expert Insight: Advantages of Carbon Ion Therapy for Bladder Cancer
- Alternative for surgically challenging tumors – Ideal for posterior wall tumors invading ureteral orifices, seminal vesicles, or prostate, where complete resection is difficult.
- Hope for chemotherapy-intolerant patients – Safer for those with bone marrow suppression or renal dysfunction.
- Superior long-term quality of life – Studies show significantly better physical and mental health scores in bladder-preserved patients vs. radical cystectomy cases.
Patient Update: Returning to Normal Life
Mr. Xu is now under regular follow-up, with stable tumor control, preserved urinary function, and has resumed daily work and light exercise.
[Closing Remarks]
The goal of bladder cancer treatment isn’t just prolonging survival—it’s safeguarding quality of life! Carbon ion therapy offers a new paradigm for recurrent/locally advanced cases: organ preservation, low toxicity, and high efficacy.
Department of Radiation Oncology VI – Heavy Ion Therapy Specialty
Pancreatic Cancer Heavy Ion Therapy Center | Abdominopelvic Tumor Heavy Ion Therapy Unit
Department Overview
The Department of Radiation Oncology VI is a specialized center for heavy ion therapy in pancreatic cancer and abdominopelvic tumors (including liver cancer, colorectal cancer, and prostate cancer), offering both heavy ion and photon radiotherapy. Since its establishment, pancreatic cancer patients from across China have sought treatment here, benefiting from precise, painless, and non-invasive tumor eradication.
To date, dozens of pancreatic cancer patients nationwide have been treated, achieving:
✔ 1-year local control rate >90%
✔ Median survival extended from 11 months (conventional therapy) to 19 months
✔ High efficacy and positive patient experience, widely recognized by domestic and international experts.
Expert Team
Our team comprises top-tier graduates from prestigious Chinese medical schools, combining solid theoretical knowledge with extensive clinical experience. Internationally renowned advisors include:Prof. Holger Hofmann (Germany)，Prof. Hirohiko Tsujii (Japan)，Prof.Yee-Min Jen (Taiwan, China)，Prof. Jia-Ming Wu (Taiwan, China).They provide complex case consultations, academic lectures, and clinical rounds. Our physicians have trained at leading heavy ion and photon therapy centers in China, ensuring cutting-edge, personalized treatment plans.
Treatment Scope
- Primary focus: Pancreatic cancer heavy ion therapy
- Extended services: Heavy ion/photon therapy for liver cancer, colorectal cancer, prostate cancer, and other abdominopelvic malignancies
- Comprehensive care: Integrated radiotherapy and individualized oncology management
Featured Specialists
Dr. Chen Weizuo
- Deputy Chief Physician & Director, Department of Radiation Oncology VI, Wuwei Cancer Hospital Heavy Ion Center
- Honors:"Luyuan Youth Talent" of Gansu ProvinceCouncil Member, Chinese Nuclear Society (Branch of Brachytherapy & Smart Radiotherapy)Youth Committee Member, Western China Radiotherapy Association
- Research:Principal Investigator for 2 provincial talent projects11 SCI papers, 5 core Chinese journal articles2 national invention patents (one awarded Gold Medal at the National Invention Exhibition)
Dr. Yin Zhaosheng
- Former Director, Radiotherapy Department, Xiangnan University Affiliated Hospital (Hunan)
- 18+ years of oncology experience
- Specialties: Precision radiotherapy (SBRT/SRS)Head & neck cancer multidisciplinary treatment
- Training: Mentored by Prof. Yee-Min Jen (ex-chair of Taiwan Radiotherapy Society)Visiting scholar at Tri-Service General Hospital & Chang Gung Memorial Hospital (Taiwan, China)